Can Patents Deter Innovation? The. Anticommons in Biomedical Research The tragedy of the anticommons is the underuse of a scare resource because the. Can patents deter innovation?: An empirical analysis of the anti-commons effect in the academic biomedical research in Milan Paperback – January 16, Heller and Eisenberg are reacting, in large part, to the growth of patenting within in biomedical science (see Murray () for more detail on.
|Published (Last):||23 February 2005|
|PDF File Size:||13.47 Mb|
|ePub File Size:||2.32 Mb|
|Price:||Free* [*Free Regsitration Required]|
Their core argument is that the anticommons emerges when the rights necessary to practice research are split up among a large number, and a large variety, of different researchers.
Can patents deter innovation? The anticommons in biomedical research
Heller and Eisenberg’s article has been cited more than 1, times in the last 12 years and has become a major article in the literature critical of patentss in science. In that sense, Murray and Stern’s article econometric article testing the hypothesis is a somewhat rough match for the theory offered.
Published in Science inHeller and Eisenberg frame their argument explicitly in terms of Hardin’s classic piece of The tragedy of the commons and applied to biomedical research although it has been used and cited as relevant more broadly. They use examples of eeter on concurrent fragments which they suggest may be creating thickets and reach-through licensing agreements to make this point.
Can patents deter innovation? The anticommons in biomedical research.
Retrieved from ” https: New Recent Changes Featured Summaries. The metaphor of the anticommons has become a frequently cited in the areas of open innovation, arguments in favor of open science, and critiques of the patent system more generally.
This page was last modified on 11 Octoberat They argue that just as too much open access to an expendable public resource can create a tragedy of the commons, too much ownership — especially an intellectual domain — can create thickets that limit the progress of science more broadly.
They end by describing why different types of organizations i. The article is often treated as argument against particular patents.
Heller and Eisenberg are reacting, in large part, to the growth of patenting within in biomedical science see Murray for more detail on case study of this in the area of mouse-research.
In fact, it’s argument is carefully crouched in terms of the problems of patents in aggregate. The anticommons in biomedical research.
Can Patents Deter Innovation? The Anticommons in Biomedical Research
Eisenberg Can patents deter innovation? They explain quite clearly that, “the tragedy of the anticommons refers to the more complex obstacles that arise when a user needs access to multiple patented inputs to create a single useful output. That said, the article seems to be somewhat missued by a number of “downstream” academics citing it.
They argue that, “privatization can solve one tragedy but cause another. Views Read View form View source View history.